Organovo (NASDAQ:ONVO) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

Shares of ONVO opened at $0.35 on Thursday. The company’s fifty day moving average price is $0.40 and its 200-day moving average price is $0.47. Organovo has a 1-year low of $0.32 and a 1-year high of $1.74. The firm has a market capitalization of $5.44 million, a PE ratio of -0.33 and a beta of 0.56.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Friday, November 8th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.12. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.04 million. Organovo had a negative net margin of 12,176.70% and a negative return on equity of 249.28%. As a group, research analysts anticipate that Organovo will post -0.77 EPS for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.